Factoring in near-term headwinds
03/12/21 -"Given the multiple near-term challenges, including the DoJ investigation w.r.t Entresto (currently second-largest drug in terms of sales) and Omicron worries perhaps delaying a long-awaited ..."
Pages
69
Language
English
Published on
03/12/21
You may also be interested by these reports :
25/03/24
Perfect execution of capacity ramp-up key for meeting targets – TP increased to CHF 81 (from CHF 75) – Reduce reiterated
21/03/24
BioNTech reported weaker than expected FY23 sales figures (-17.7%), explained by the structure of the partnering deal with Pfizer. However, investors ...
20/03/24
FDA approves TRYVIO (aprocitentan) for hypertension
19/03/24
Family controlled UCB (ADD; Belgium) has been one of the strongest performing pharma stocks (+36% in the share price) in 2024. While the recent surge ...